Deerfield Beach, FL -- (SBWIRE) -- 07/25/2016 -- IVIG is a sterile solution of antibodies collected from healthy donors, which is administered through the veins into the body. Currently, the Immunoglobulin industry is growing on account of increasing FDA/EMA approvals and government support. IVIG usage against the conditions within the criteria (i.e. FDA/EMA approved indications) have increased greatly and the largest increase found in Chronic Inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia and immunodeficiency diseases.

In addition, there has been a substantial increase in IVIG prescriptions for the treatment of off-label indications, such as, specific antibody deficiency, Guillain-Barre syndrome, Inflammatory Myopathies and others. However, factors such as the high cost of IVIG treatment, side effects associated with use of IVIG, stringent government regulations and a lengthy product approval process would hamper its market growth. Despite several challenges such as inadequate supply of immunoglobulins, stringent regulatory policies and the high cost associated with IVIG treatments, the global IVIG market would witness notable growth during the forecast period.

Get Free Sample Report of Intravenous Immunoglobulin Market: http://www.intenseresearch.com/market-analysis/global-intravenous-immunoglobulin-market-by-application-types-and.html#request-sample

Global IVIG market is segmented based on its types, application and geography. The application segment includes Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency diseases, Congenital AIDS, Chronic Lymphocytic Leukaemia (CLL), Myasthenia Gravis, Multifocal motor neuropathy, Idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barre syndrome, and others. Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP) holds a dominant share in the market due to a large patient population and the unavailability of effective alternatives for IVIG treatment.

Geographically, the report covers five key regions, North America, Europe, Asia Pacific, and LAMEA. Presently, North America occupies a majority of the market followed by the Asia Pacific region. High adoption of IVIG therapies and a large pool of patient population in the North American region is a prime factor responsible for the growth of the North America IVIG market. However, in the Asia-pacific region, growing awareness for immunodeficiency disease & neurological disorders along with the increasing preference towards IVIG therapies, largely drives the market. The companies profiled in this report include Baxter international Inc., CSL Limited, Grifols S.A, Octapharma Ag, Kedrion Pharma, LFB group, Biotest AG, china Biologics products Ltd, Bayer Healthcare, and others.

Get Full Table Of Content (Index) Of Intravenous Immunoglobulin Market: http://www.intenseresearch.com/market-analysis/global-intravenous-immunoglobulin-market-by-application-types-and.html#table-of-content

Table Of Content Of Intravenous Immunoglobulin Market:

CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segment
1.4 Research methodology
1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
2.2 Market beyond what to expect by 2026 ($Million)
2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario

CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Overview of Intravenous Immunoglobulin (IVIG)
3.2.1 Patented products
3.3 Epidemiology and economic burden of chronic conditions
3.4 Cost of side effects due to IVIG treatments
3.5 Key findings
3.5.1 Top Factors Impacting global intravenous immunoglobulin market
3.5.2 Top Investment pockets – Global Intravenous Immunoglobulin Market

About Intense Research
Intense Research provides a range of marketing and business research solutions designed for our client's specific needs based on our expert resources. The business scopes of Intense Research cover more than 30 industries includsing energy, new materials, transportation, daily consumer goods, chemicals, etc. We provide our clients with one-stop solution for all the research requirements.

Contact Us:
Joel John
3422 SW 15 Street, Suite #8138,
Deerfield Beach, Florida 33442,
United States
Tel: 386-310-3803
GMT Tel: +49-322 210 92714
USA/Canada Toll Free No. 855-465-4651
Email: sales@intenseresearch.com
Web: http://www.intenseresearch.com/